1015 Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
1015 Capital Partners's VRTX Position: Q3 2026 in Review
1015 Capital Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2026, closing a stake of 7 shares — an estimated $3.48K sold.
1015 Capital Partners first reported a position in VRTX in Q4 2025 and held it in 3 quarters. The position peaked at $3.48K in Q2 2026. 1,796 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.
- 1015 Capital Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
- 1015 Capital Partners sold 7 Vertex Pharmaceuticals shares in Q3 2026, an estimated $3.48K.
- 1015 Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2025 and held it in 3 quarters.
- 1015 Capital Partners's Vertex Pharmaceuticals position peaked at $3.48K in Q2 2026.
- 1,796 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.
Based on 1015 Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.